News

  • 7 March 2019

    Zealand Pharma begins dosing in Phase III trial for CHI

    Danish biotechnology company Zealand Pharma has started treating patients in a Phase III clinical trial being carried out to investigate dasiglucagon for the treatment of congenital hyperinsulinism (CHI) in children.

  • 7 March 2019

    Almac Group unveils new clinical trial supply solution

    Almac Group, a UK-based contract development and manufacturing company, has unveiled a unified clinical trial supply solution to improve experience for sponsors. Dubbed Almac ONE, the new platform is intended...

Close
Close
Close

Go Top